Leica Biosystems to Acquire StatLab Medical Products from Linden Capital Partners and Audax Private Equity
Linden Capital Partners (“Linden”) and Audax Private Equity (“Audax”), two prominent middle-market private equity investment firms with extensive experience in the healthcare sector, have entered into a definitive agreement to sell StatLab Medical Products (“StatLab”) to Leica Biosystems, a global leader in anatomic pathology solutions and an operating company of Danaher Corporation (NYSE: DHR). The proposed acquisition represents a significant milestone for StatLab as it prepares to begin a new phase of growth under the ownership of one of the world’s leading life sciences and diagnostics organizations.
The transaction, which remains subject to customary regulatory approvals and standard closing conditions, underscores the continued consolidation within the pathology and laboratory diagnostics industry as organizations seek to expand their product offerings, manufacturing capabilities, and global customer reach.
StatLab’s Journey from Regional Supplier to Global Manufacturer
Founded in 1976 and headquartered in McKinney, Texas, StatLab Medical Products has established itself as one of the leading manufacturers of pre-analytical products used throughout the anatomic pathology workflow. Over nearly five decades, the company has earned a reputation for producing reliable laboratory consumables and workflow solutions while maintaining high standards of quality, customer service, and operational excellence.
Today, StatLab serves hospital laboratories, diagnostic centers, research institutions, distributors, and original equipment manufacturer (OEM) partners throughout the United States and Europe. Its portfolio supports laboratories by providing products that improve efficiency, consistency, and reliability across the pathology preparation process.
The company’s expertise in manufacturing, combined with its customer-focused approach, has enabled it to become an important supplier in a market where precision, quality control, and dependable service are essential.
Strategic Growth Under Linden and Audax Ownership
Since Linden Capital Partners and Audax Private Equity partnered with StatLab in 2021, the company has undergone a period of significant transformation and expansion. Rather than simply increasing revenues, the investment strategy focused on strengthening StatLab’s long-term competitive position by expanding manufacturing capabilities, broadening the product portfolio, investing in talent, and increasing international presence.
During the ownership period, StatLab evolved from being primarily a U.S.-focused organization into a more diversified global manufacturer with integrated production capabilities.
The private equity partners supported investments across multiple strategic areas, including:
- Expansion of leadership and management teams.
- Strengthening commercial and sales operations.
- Investments in manufacturing facilities.
- Enhanced research and operational capabilities.
- Improved customer engagement initiatives.
- Expansion into international markets.
- Growth through strategic acquisitions.
These initiatives positioned StatLab to better serve laboratories and healthcare organizations while creating a stronger operational foundation for future growth.
Building Manufacturing Strength
A major priority throughout the investment period involved expanding StatLab’s self-manufacturing capabilities. Rather than relying extensively on third-party production, the company increased its internal manufacturing capacity, allowing greater control over product quality, production timelines, innovation, and supply chain reliability.
Strengthening manufacturing infrastructure also improved operational flexibility while enabling the company to respond more effectively to customer demand across multiple geographic markets.
The investments ultimately created a more resilient manufacturing platform capable of supporting continued growth both organically and through acquisitions.
Nine Strategic Acquisitions Accelerated Growth
One of the defining features of StatLab’s transformation under Linden and Audax was an active acquisition strategy.
Over the course of the investment, the company completed nine strategic acquisitions designed to expand manufacturing capabilities, strengthen product offerings, and increase market reach.
These acquisitions allowed StatLab to:
- Add complementary pathology products.
- Increase manufacturing expertise.
- Expand production capacity.
- Enhance vertical integration.
- Strengthen customer relationships.
- Broaden distribution capabilities.
- Support innovation across the pathology workflow.
Rather than pursuing acquisitions solely for scale, the company focused on integrating businesses that aligned with its long-term vision of becoming a comprehensive provider across the anatomic pathology ecosystem.
Leadership Reflects on the Transformation
Joe Bernardo, Chairman of StatLab and Linden Operating Partner, reflected on the company’s progress since Linden became involved in 2021.
He explained that Linden recognized both StatLab’s longstanding reputation for quality and customer service as well as the opportunity to develop a larger, fully integrated manufacturing platform capable of supporting laboratories throughout the complete anatomic pathology workflow.
According to Bernardo, the company has successfully executed that vision through strategic investments, operational improvements, and innovation.
He noted that StatLab has emerged from the partnership stronger, more innovative, and significantly more global than when the investment began. Bernardo also expressed confidence that the company will continue to thrive under Leica Biosystems and Danaher, where additional resources and global reach can further accelerate growth.
CEO Highlights Team Achievement
StatLab Chief Executive Officer Sung-Dae Hong credited much of the company’s success to its employees and the support provided by Linden and Audax throughout the investment period.
He thanked both investment firms for providing the financial resources and strategic guidance needed to accelerate the company’s expansion while allowing management to remain focused on serving customers.
Hong emphasized that StatLab’s accomplishments reflect the dedication of its workforce as well as the trust placed in the company by laboratory customers, distributors, and OEM partners.
He also described joining Danaher through Leica Biosystems as recognition of the company’s progress and reaffirmed that StatLab’s commitment to delivering high-quality products and supporting customers would remain unchanged following the acquisition.
Audax Highlights Strategic Execution
Stephen Weaver, Managing Director at Audax Private Equity, together with Partner David Wong, praised StatLab’s management team for successfully executing an ambitious growth strategy.
They noted that management combined disciplined acquisition activity with meaningful investments in manufacturing infrastructure, operational capabilities, and talent development.
According to Audax, these initiatives transformed StatLab into a distinguished global provider serving the anatomic pathology market while creating substantial long-term value.
The firm’s leadership also expressed appreciation for the collaborative partnership with Linden Capital Partners throughout the investment period.
Linden Recognizes Company Milestone
Kam Shah, Partner at Linden Capital Partners, congratulated StatLab’s leadership and employees on reaching an important milestone in the company’s history.
He highlighted several major accomplishments achieved during Linden’s investment, including:
- Development of a dual-continent manufacturing footprint.
- Expansion of the company’s product portfolio.
- Strengthening customer relationships.
- Increased manufacturing capabilities.
- Enhanced operational scale.
- Continued reputation for quality and service.
Shah also acknowledged the close collaboration between Linden and Audax throughout the ownership period, noting that the successful transaction reflects years of coordinated effort focused on long-term value creation.
Experienced Board Supported Growth Strategy
StatLab benefited from guidance provided by an experienced Board of Directors representing expertise across healthcare, diagnostics, manufacturing, and corporate strategy.
In addition to Joe Bernardo, the board includes:
- Brian Miller, Co-Founder and Partner at Linden Capital Partners.
- Kim Kelderman, Chief Executive Officer of Bio-Techne.
- Gary Knight, former Vice President of Strategy & Corporate Development at VWR.
The board’s collective industry knowledge helped guide strategic decisions during a period marked by expansion, acquisitions, and operational transformation.
Leica Biosystems Expands Its Portfolio
For Leica Biosystems, the acquisition represents another strategic investment aimed at strengthening its leadership position within anatomic pathology.
Leica Biosystems develops comprehensive pathology workflow solutions used by laboratories worldwide, including tissue processing systems, staining platforms, digital pathology technologies, and diagnostic instruments.
The addition of StatLab’s pre-analytical products and manufacturing capabilities is expected to complement Leica’s existing portfolio while expanding its ability to provide integrated workflow solutions across the pathology laboratory.
As part of Danaher Corporation, Leica Biosystems also benefits from access to extensive global resources, research capabilities, manufacturing expertise, and international commercial infrastructure.
The acquisition aligns with Danaher’s broader strategy of expanding its presence in life sciences, diagnostics, and healthcare technologies through targeted acquisitions of innovative businesses.
Continued Focus on Customers
Throughout the announcement, company executives consistently emphasized that customer relationships remain central to StatLab’s future.
Laboratories, distributors, healthcare providers, and OEM customers are expected to continue receiving the same commitment to quality products, dependable service, and operational support that have defined the company’s reputation for decades.
The expanded resources available through Leica Biosystems and Danaher may also create opportunities to accelerate product innovation, improve manufacturing efficiency, and broaden global market access.
Financial and Legal Advisors
The transaction is being supported by experienced financial and legal advisory firms.
Moelis & Company served as the exclusive financial advisor to StatLab during the transaction process.
Legal counsel for Linden Capital Partners and Audax Private Equity was provided by Ropes & Gray LLP and Kirkland & Ellis LLP.
Completion of the acquisition remains subject to customary closing conditions and regulatory approvals.
Once finalized, the transaction will mark the beginning of a new chapter for StatLab Medical Products as it joins Leica Biosystems and Danaher, positioning the company to continue expanding its global presence while supporting laboratories with innovative pathology products and manufacturing excellence.
Source link: https://www.businesswire.com
